HealthCare Royalty Partners secured $1.83 billion at the close of its Healthcare Royalty Partners IV LP vehicle and affiliated funds.
The Stamford, Conn.-based private investment firm received capital from new and existing partners.
HealthCare Royalty will use the raised funds to buy royalties and revenue interests from commercial biopharmaceutical products and provide debt financing with mainly commercial stage assets as collateral. The firm typically invests between $20 million and $200 million.
Additionally, HealthCare Royalty promoted four individuals to managing director, including Carlos Almodóvar, head of investor relations; Shin Kang, head of research; Andrew Reardon, chief legal officer; and Spencer Schneider, chief compliance officer and intellectual property counsel.